scholarly journals Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome

2015 ◽  
Vol 36 (6) ◽  
pp. 708-715 ◽  
Author(s):  
Feng-yun Wang ◽  
Min Su ◽  
Yong-qiu Zheng ◽  
Xiao-ge Wang ◽  
Nan Kang ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Mucosal Barrier ◽  
Intestinal Mucosal Barrier ◽  
Irritable Bowel ◽  
Herbal Prescription

scholarly journals Intestinal Mucosal Barrier Is Regulated by Intestinal Tract Neuro-Immune Interplay

2021 ◽  
Vol 12 ◽  
Author(s):  
Xin-yu You ◽  
Han-yu Zhang ◽  
Xu Han ◽  
Fang Wang ◽  
Peng-wei Zhuang ◽  
...  
Keyword(s):  
Nervous System ◽  
Metabolic Diseases ◽  
Intestinal Inflammation ◽  
Acute Stress ◽  
Intestinal Barrier ◽  
Cerebrovascular Diseases ◽  
Mucosal Barrier ◽  
Intestinal Mucosal Barrier ◽  
Mucosal Barrier Function ◽  
Irritable Bowel

Inflammatory bowel disease, irritable bowel syndrome and severe central nervous system injury can lead to intestinal mucosal barrier damage, which can cause endotoxin/enterobacteria translocation to induce infection and is closely related to the progression of metabolic diseases, cardiovascular and cerebrovascular diseases, tumors and other diseases. Hence, repairing the intestinal barrier represents a potential therapeutic target for many diseases. Enteral afferent nerves, efferent nerves and the intrinsic enteric nervous system (ENS) play key roles in regulating intestinal physiological homeostasis and coping with acute stress. Furthermore, innervation actively regulates immunity and induces inherent and adaptive immune responses through complex processes, such as secreting neurotransmitters or hormones and regulating their corresponding receptors. In addition, intestinal microorganisms and their metabolites play a regulatory role in the intestinal mucosal barrier. This paper primarily discusses the interactions between norepinephrine and β-adrenergic receptors, cholinergic anti-inflammatory pathways, nociceptive receptors, complex ENS networks, gut microbes and various immune cells with their secreted cytokines to summarize the key roles in regulating intestinal inflammation and improving mucosal barrier function.

scholarly journals Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions

2016 ◽  
Vol 311 (5) ◽  
pp. G777-G784 ◽  
Author(s):  
Michael Camilleri ◽  
Ibironke Oduyebo ◽  
Houssam Halawi
Keyword(s):  
Fatty Acids ◽  
Irritable Bowel Syndrome ◽  
Molecular Mechanisms ◽  
Current Knowledge ◽  
Short Chain Fatty Acids ◽  
Mucosal Barrier ◽  
Future Research ◽  
Enteroendocrine Cell ◽  
The Central Nervous System ◽  
Irritable Bowel

Several chemical and molecular factors in the intestine are reported to be altered and to have a potentially significant role in irritable bowel syndrome (IBS), particularly in IBS with diarrhea. These include bile acids; short-chain fatty acids; mucosal barrier proteins; mast cell products such as histamine, proteases, and tryptase; enteroendocrine cell products; and mucosal mRNAs, proteins, and microRNAs. This article reviews the current knowledge and unanswered questions in the pathobiology of the chemical and molecular factors in IBS. Evidence continues to point to significant roles in pathogenesis of these chemical and molecular mechanisms, which may therefore constitute potential targets for future research and therapy. However, it is still necessary to address the interaction between these factors in the gut and to appraise how they may influence hypervigilance in the central nervous system in patients with IBS.

scholarly journals Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls

2011 ◽  
Vol 301 (5) ◽  
pp. G919-G928 ◽  
Author(s):  
Archana S. Rao ◽  
Michael Camilleri ◽  
Deborah J. Eckert ◽  
Irene Busciglio ◽  
Duane D. Burton ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Diseases ◽  
Oral Solution ◽  
Mucosal Barrier ◽  
Healthy Controls ◽  
Barrier Dysfunction ◽  
Capsule Formulation ◽  
Mucosal Permeability ◽  
Irritable Bowel

Mucosal barrier dysfunction contributes to gastrointestinal diseases. Our aims were to validate urine sugar excretion as an in vivo test of small bowel (SB) and colonic permeability and to compare permeability in patients with irritable bowel syndrome-diarrhea (IBS-D) to positive and negative controls. Oral lactulose (L) and mannitol (M) were administered with 99mTc-oral solution, 111In-oral delayed-release capsule, or directly into the ascending colon (only in healthy controls). We compared L and M excretion in urine collections at specific times in 12 patients with IBS-D, 12 healthy controls, and 10 patients with inactive or treated ulcerative or microscopic colitis (UC/MC). Sugars were measured by high-performance liquid chromatography-tandem mass spectrometry. Primary endpoints were cumulative 0–2-h, 2–8-h, and 8–24-h urinary sugars. Radioisotopes in the colon at 2 h and 8 h were measured by scintigraphy. Kruskal-Wallis and Wilcoxon tests were used to assess the overall and pairwise associations, respectively, between group and urinary sugars. The liquid in the colon at 2 h and 8 h was as follows: health, 62 ± 9% and 89 ± 3%; IBS-D, 56 ± 11% and 90 ± 3%; and UC/MC, 35 ± 8% and 78 ± 6%, respectively. Liquid formulation was associated with higher M excretion compared with capsule formulation at 0–2 h (health P = 0.049; IBS-D P < 0.001) but not during 8–24 h. UC/MC was associated with increased urine L and M excretion compared with health (but not to IBS-D) at 8–24 h, not at 0–2 h. There were significant differences between IBS-D and health in urine M excretion at 0–2 h and 2–8 h and L excretion at 8–24 h. Urine sugars at 0–2 h and 8–24 h reflect SB and colonic permeability, respectively. IBS-D is associated with increased SB and colonic mucosal permeability.

scholarly journals Giardiasis and post-infectious bowel syndrome

2021 ◽  
pp. 178-187
Author(s):  
A. A. Belova ◽  
M. D. Shestakova ◽  
A. I. Khavkin
Keyword(s):  
Immune Response ◽  
Irritable Bowel Syndrome ◽  
Gastrointestinal Tract ◽  
Species Composition ◽  
Intestinal Microbiota ◽  
Mucosal Barrier ◽  
Irritable Bowel ◽  
The Moment ◽  
High Level ◽  
Post Infectious

Post-infectious irritable bowel syndrome — one of the most frequent conditions diagnosed in pediatric gastroenterological practice. According to numerous research parisitosis contributes to the chronology of gastrointestinal tract pathology. it is known that the infection Lamblia intestinalis can increase the risk of developing post-infectious IBS, changing species composition and diversity of the intestinal microbiota, modulating metabolism of the host, the nature of the immune response and adversely affecting the mucosal barrier and the motility of the digestive tract. Importantly, the prevalence of giardiasis in patients with symptoms of IBS and dyspepsia at the moment, it remains at a high level. Further research into the pathogenesis of Lamblia intestinalis infection in patients with IBS will be of great importance in medicine.

Sign in / Sign up

Export Citation Format

Share Document